"Making specialty medicines accessible to all"
We manufacture and market affordable medicines that comply with global standards and strive to achieve market leadership in domestic and international markets
NATCO launched the 1st generic version of Oseltamivir Capsules – in the United States in collaboration with our marketing partner, Alvogen during the flu season in December 2016. NATCO, being the only generic player during this flu season, makes this launch a notable blockbuster!
Our products cover three main markets; international formulations, domestic formulations and APIs. Within these areas we are leaders in generic oncology and are taking steps to expand therapeutic segments with a continued focus on niche products.
Natco Trust was founded in 1995 with the desire to serve under-privileged children and poor people in society. As National Award winners For Excellence in CSR & Sustainability, we strongly believe in giving back to the communities in which we function.
In FY 2016-17, NATCO's revenue from operations on a consolidated basis amounted to ₹ 20,789 million vis-a-vis ₹ 10,897 million in FY 2015-16, recording a 31.29% CAGR over the last five years.
Share price at
Oct 17 - Close
Share price at
Oct 18 - Close
We provide a stimulating and challenging work environment for our employees, who get the opportunity to work with state-of-the-art technologies and deliver affordable and life saving drugs globally.
Whether you're a customer, job seeker, health professional or an investor, you can find the best way to contact us.